Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530166 · ClinicalTrials.gov registry record · Phase 2
Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.
A Phase 2 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Terminated
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT00530166 is a Phase 2 study that was terminated before completion, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 26 participants.
The verdict
NCT00530166, a Phase 2 study, was terminated before completion, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effectiveness of JNJ-18054478 measured by the percent change from baseline in Forced Expiratory Volume in one Second (FEV1) after 12 weeks of therapy in patients with persistent asthma.
Interventions
- DRUG JNJ-18054478
- DRUG sham comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530166
The ClinicalTrials.gov registry entry for NCT00530166 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which JNJ-18054478 is the first listed.
NCT00530166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530166 about?
NCT00530166 is a clinical study titled "Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.". The purpose of this study is to assess the effectiveness of JNJ-18054478 measured by the percent change from baseline in Forced Expiratory Volume in one Second (FEV1) after 12 weeks of therapy in patients with persistent asthma.
What is the current status of trial NCT00530166?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2007-07. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00530166?
The interventions under investigation include: JNJ-18054478 (DRUG), sham comparator (DRUG).
Who is sponsoring clinical trial NCT00530166?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.